加载中
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
前收盘价
US$1.10
−US$0.025 · -2.22%
盘前
US$1.06
−US$0.04 · -3.64%
10月12日 8:10 ET
盘中时间采用ET。市场数据可能有所延迟。
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
日内区间
当前US$1.10
52周区间
当前US$1.10
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
46
合理估值
情绪
56
多空交织
风险
86
极高风险
动量
25
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
日内区间
当前US$1.10
52周区间
当前US$1.10
营业利润
净利润
| 项目（GBP） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 1273.7万 GBP | 1801.7万 GBP | 2506.2万 GBP | 3642.6万 GBP | 3683.4万 GBP |
| 销售、一般及管理费用 | 809.6万 GBP | 498.8万 GBP | 606.3万 GBP | 729.1万 GBP | 852.9万 GBP |
| 营业费用 | 2011万 GBP | 2280.9万 GBP | 3278.4万 GBP | 3912.2万 GBP | 4790.5万 GBP |
| 利息收入 | 38.6万 GBP | 35.8万 GBP | 75.4万 GBP | 66.9万 GBP | 10.3万 GBP |
| 折旧和摊销 | 27.4万 GBP | 52.2万 GBP | 57.5万 GBP | 73.2万 GBP | 94.2万 GBP |
| 营业利润 | −2011万 GBP | −2280.9万 GBP | −3278.4万 GBP | −3912.2万 GBP | −4790.5万 GBP |
| 净利润 | −2935.3万 GBP | −1899.7万 GBP | −2763.2万 GBP | −3202.1万 GBP | −4053.3万 GBP |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年8月8日 | 1:200 | — | — |
股票拆分 | 2024年4月16日 | 1:25 | — | — |
已生效 2025年8月8日
1:200
已生效 2024年4月16日
1:25
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
